Cocrystal Pharma Gets FDA Fast Track for Norovirus Treatment & Prevention
FDA fast-tracks a new oral drug, CDI-988, to treat and prevent norovirus—a common stomach virus affecting millions worldwide.
/ 2 items
FDA fast-tracks a new oral drug, CDI-988, to treat and prevent norovirus—a common stomach virus affecting millions worldwide.
Cocrystal's CDI-988 is a new oral drug that may prevent/treat norovirus, the stomach bug. It targets a viral enzyme, shows broad-spectrum activity & good safety in early studies. FDA approved next study for this potential first-of-its-kind antiviral.